Inneke Van De Vijver
Datos Biográficos
| ID | 9570336 |
|---|---|
| NOMBRE | Inneke Van De Vijver |
| NOMBRES | Inneke |
| APELLIDO | Van De Vijver |
| FIRMA | VAN DE VIJVER I |
| AFILIACIONES | Rijksinstituut voor Ziekte- en Invaliditeitsverzekering |
| VERIFICADO | No |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 1 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2024 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2024 |
| ÍNDICE H | 0 |
Availability and financing of CAR-T cell therapies
Chimeric antigen receptor T-cell therapies (CAR-T therapies) are a type of advanced therapy medicinal product (ATMP) that belong to a new generation of personalised cancer immunotherapies. This paper compares the approval, availability and financing of CAR-T cell therapies in ten countries. It also examines the implementation of this type of ATMP within the health care system, describing the organizational elements of CAR-T therapy delivery and t…
Sin obras prominentes en esta página.
Availability and financing of CAR-T cell therapies
Chimeric antigen receptor T-cell therapies (CAR-T therapies) are a type of advanced therapy medicinal product (ATMP) that belong to a new generation of personalised cancer immunotherapies. This paper compares the approval, availability and financing of CAR-T cell therapies in ten countries. It also examines the implementation of this type of ATMP within the health care system, describing the organizational elements of CAR-T therapy delivery and t…
Biomedical Ethics and Regulation (1 obras) · Biosimilars and Bioanalytical Methods (1 obras) · Business (1 obras) · CAR-T cell therapy research (1 obras) · Finance (1 obras)